Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

cing related costs

---15.0Restructuring & other special items

15.431.846.062.3Tax effect of the above items

(53.2)(79.7)(130.2)(165.9)Preferred dividend (b)

-34.8-104.3Adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS

$237.8

$0.55$189.0

$0.43$666.5

$1.51$510.6

$1.16Weighted average diluted common shares outstanding (b)

431.6437.9441.8438.2(a)  Purchase accounting related amortization expense for the three and nine months ended September 30, 2011 includes a $16.2 million in-process research and development asset impairment charge.   (b)  Adjusted diluted EPS for the three and nine months ended September 30, 2010, was calculated under the "if-converted method" which assumes conversion of the company's preferred stock into 125.2 million shares of common stock, based on an average share price, and excludes the preferred dividend from the calculation, as the "if-converted method" is more dilutive.Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. to adjusted EBITDA for the three and nine months ended September 30, 2011, and 2010 (in millions):  Three months ended September 30,Nine months ended September 30,2011201020112010GAAP net earnings attributable to Mylan Inc. before preferred dividends

$
56.7$
43.2$
407.3$
325.3Add/(Deduct):Net contribution attributable to the noncontrolling interest and equity method investees

0.70.41.6(0.6)Income taxes

34.8(12.0)116.933.3Interest expense

85.887.5254.8240.0Depreciation and amortization (a)

141.7108.0386.6312.9EBITDA

$
419.7$
327.1$ 1,167.2$
910.9Add Adjustments:Stock-based compensation expense

11.68.532.824.1Litigation settlements, net

2.21.528.514.3Restructuring & other special items

13.431.042.176.5Adjusted EBITDA

$
446.9$
368.1$ 1,270.6$ 1,025.8(a) Depreciation and amortization expense fo
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... Calif. , April 22, 2015 ... and analytics, announced today that it has opened ... its continued growth and expansion.  The common stock ... Act, Section 506(c), a law intended to encourage ... regulations.  Prior to 506(c), small businesses largely relied ...
(Date:4/22/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... to initiate a Phase 1 pharmacokinetic and biomarker ... Biohaven plans to initiate the trial no later ... in the Phase 1 study, Biohaven will move ...
Breaking Biology Technology:Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 2Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 3
... , , , , ... Inc.,(Nasdaq: SSRX ), a leading biotechnology company focused ... today announced that it has submitted its application for ... Drug,Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme ...
... , , ... enrollment of patients with acute ischemic stroke into its,Phase III ... at the Wolfson Medical Center, Israel. The MACSI trial involves,numerous ... Korea and Brazil. DP-b99 is D-Pharm,s most advanced product developed,for ...
... WASHINGTON, Dec. 29 The National Fragile X Foundation applauds ... Fragile X Syndrome for the first time ever within a ... U.S. Department of Defense. , The new law, ... through the FY 2010 Department of Defense Appropriations Act for ...
Cached Biology Technology:3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3Defense Department to Support Fragile X Research 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... have discovered how two closely related proteins guide projections ... repelling these axons as they navigate the most miniscule ... remarkably precise connections. The discovery, reported April 28 ... belonging to the "semaphorin" family of guidance cues are ...
... As part of the Genome Canada Large-Scale Applied Research ... million to 16 projects across the country, the researchers ... function with the aim of identifying genes or proteins ... to target cancers and other diseases. The first ...
... by a parasitic fungus dramatically changes the behavior of tropical ... to become zombie-like and to die at a spot that ... team studied ants living high up in the rainforest canopy ... in the BioMed Central open-access journal BMC Ecology ...
Cached Biology News:Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3Zombie ants have fungus on the brain, new research reveals 2